Browse
Submit Data
Databases
API
Help

Dataset Information

203 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of triple negative breast cancer cell lines

ABSTRACT: We analysed aquired chemotherapeutic resistance of two different triple negative breast cancer cell lines BT-549 (Doxorubicin resistance) and MDA-MB-468 (5-Fluorouracil) by comparing the proteome of the parental cell line with the resistant cell line.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: Florian Bonn

LAB HEAD: Donat Kögel

PROVIDER: PXD008522 | Pride | 2018-02-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.

Das Chandan Kanta CK Linder Benedikt B Bonn Florian F Rothweiler Florian F Dikic Ivan I Michaelis Martin M Cinatl Jindrich J Mandal Mahitosh M Kögel Donat D

Neoplasia (New York, N.Y.) 20180222 3

Target-specific treatment modalities are currently not available for triple-negative breast cancer (TNBC), and acquired chemotherapy resistance is a primary obstacle for the treatment of these tumors. Here we employed derivatives of BT-549 and MDA-MB-468 TNBC cell lines that were adapted to grow in the presence of either 5-Fluorouracil, Doxorubicin or Docetaxel in an aim to identify molecular pathways involved in the adaptation to drug-induced cell killing. All six drug-adapted BT-549 and MDA-MB ...[more]

PMID: 29462756

Similar Datasets

RNA-Sequencing analysis of Meox1 siRNA knockdown in p53 and PTEN deficient triple negative breast cancer in vitro cell lines of BT-549 and MDA-MB-468

Project description:The goal for this experiment was to analyze how knockdown of homeobox transcription factor Meox1 altered functional and mechanist biology of p53 and PTEN deficient triple negative breast cancer in vitro cell lines of claudin-low BT-549 and basal-like MDA-MB-468.

2020-05-26 | GSE133927 | GEO

Effects of siRNA targeting PRKCD in breast cancer cells

Project description:The aim was to identify genes that were commonly influenced by a siRNA targeting PRKCD in breast cancer cell lines. MDA-MB-468 and BT-549 breast cancer cell lines were treated with control siRNA or siRNA targeting PRKCD. Three samples in each group were analyzed.

2015-03-01 | E-GEOD-55503 | biostudies-arrayexpress

microRNA profiling of luminal and TNBC breast cancer cell lines

Project description:two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549

2014-10-03 | GSE62022 | GEO

microRNA profiling of luminal and TNBC breast cancer cell lines

Project description:two luminal cell lines were added, MCF7 and BT-474 two TNBC cell line were added, MB231 and BT-549 microRNA expression profiles were conpared between the luminal group and the TNBC group

2014-10-03 | E-GEOD-62022 | biostudies-arrayexpress

Restoring miR-150-5p to a triple negative breast cancer cell line [BT-549]

Project description:The objective of these experiments is to identify novel direct and indirect targets of miR-150-5p in breast cancer cell lines. The goal is that these will give direction as to what targets or pathways may be contributing to the reduced growth observed in these cell lines upon restoration of miR-150-5p. A therapy directed towards one or more critical subtype-specific targets could be developed as a therapeutic for breast cancer patients. Using has-miR-150-5p mirVana miRNA mimic (Ambion, 4464066), miR-150-5p was restored to a triple negative breast cancer cell line, BT-549.

2017-01-01 | GSE87589 | GEO

Targeted inhibition of LIFR enhances therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Project description:Here, we examined the therapeutic utility of EC359 in improving the therapeutic efficacy of HDACi in TNBC models. BT-549 cells were treated with vehicle (DMSO), EC359, HDACi(Vorinostat), EC359+HDACi and the RNA was isolated and utilized for RNA-seq analysis. Our results demonstrated that the beneficial effect of the EC359+HDACi involves regulation of multiple genes that involved in several pathways including apoptosis, metabolism and cell cycle.

2021-12-02 | GSE163249 | GEO

Proteomics analysis of Polyphyllin D-treated triple-negative breast cancer cells reveal the anticancer mechanisms of Polyphyllin D

Project description:Polyphyllin D (PD) is the active component from an Asian traditional medicinal herb Paris polyphylla, and has been found to hold significant anticancer activity in vivo or in vitro. However, the mechanism through which PD exerts its anticancer effects in triple-negative breast cancer (TNBC) remains unclear. Our study was presented to evaluate the anticancer effect and the potential mechanisms of PD in two TNBC cell lines, namely BT-549 and MBA-MB-231. Through comprehensively comparing the liquid chromatography-tandem mass spectrometry (LC-MS/MS) data of PD-treated and -untreated BT-549 and MBA-MB-231 cells, we found PD could activate oxidative phosphorylation pathway in BT-549 cells and inhibit spliceosome function in MDA-MB-231 cells, suggesting that the anticancer effect of PD may be cell type-specificity dependent. Moreover, we found that nodal modulator 2/3 (NOMO2/3) were down-regulated both in PD-treated BT-549 and MBA-MB-231 cells, suggesting NOMO2/3 may be the potential target of PD. Whether NOMO2/3 are the upstream modulators of oxidative phosphorylation pathway and Spliceosome need further validation. In conclusion, a comprehensive proteomics study was performed on PD-treated or untreated TNBC cells, revealing the anticancer mechanisms of PD.

2023-03-20 | PXD040990 | iProX

Metabolomics Analysis of Triple Negative Breast Cancer (BCa) Cell Lines

Project description:We used untargeted metabolomic profiling to distinguish this form of BCa from estrogen receptor positive (ER+) subtypes (+/- HER2/neu) and determine that may explain why a commonly used chemotherapeutic, paclitaxel, is generally ineffective at eliciting long-term cytotoxic and/or cytostatic responses in cell line models of TNBC. This metabolomics study used broad spectrum 1H NMR to compare Luminal A (BT474, MCF-7) and triple-negative (MDA-MB-231, MDA-MB-468) BCa cell lines, to determine differences in the two subtypes as well as distinguish therapeutic treatment responses for identifying new targets for drug discovery.

2016-08-02 | ST000442 | MetabolomicsWorkbench

Transgelin silencing induces different processes in differrent breast cancer cell lines

Project description:Transgelin is a protein which has been described as a marker of several cancers. Interestingly, the literature describes both up- and down-regulation of transgelin in the tumor in comparison with non-tumor tissue. The mechanisms of transgelin function in cancer are considerably unknown. Transgelin is abundant especially in smooth muscle cells. It is associated with actin stress fibers. These contractile structures participate among others in cell motility, adhesion or morphology. We focused on transgelin function in breast cancer. Initially, we studied transgelin role in cell migration in the breast cancer cell lines BT 549 and PMC 42. Using xCELLigence system we reached opposite results in two cell lines. Transgelin silencing increased and decreased migration of PMC 42 and BT 549 cells, respectively. To further clarify these contradictory results, we performed an experiment to quantify proteomic changes after transgelin silencing in these two cell lines using quantitative proteomics (iTRAQ-2DLC-MS/MS). Our results confirmed transgelin function in the migration of BT 549 cells and suggested transgelin role in apoptosis and small molecule biochemistry in PMC 42 cells.

2020-02-21 | PXD016316 | Pride

Genes involved in doxorubicin drug resistance in 143b osteosarcoma cell line

Project description:The study was done to identify the differentially expressed genes in response to Doxorubicin drug resistance in the 143B human osteosarcoma cell line, using the Microarray technology. Keywords: drug resistance; dual channel; cell line based; doxorubicin resistance; Human osteosarcoma cell line

2007-03-01 | GSE3362 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data